Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton

Bioorg Med Chem. 2015 Jan 15;23(2):328-39. doi: 10.1016/j.bmc.2014.11.027. Epub 2014 Dec 2.

Abstract

Human sirtuin 2 (SIRT2) is an attractive target molecule for development of drugs to treat neurodegenerative diseases and cancer, because SIRT2 inhibitors have a protective effect against neurodegeneration and an anti-proliferative effect on cancer stem cells. We designed and synthesized a series of benzamide derivatives as SIRT2 inhibitor candidates. Among them, compound 17k showed the most potent SIRT2-inhibitory activity (IC50=0.60μM), with more than 150-fold selectivity over SIRT1 and SIRT3 isoforms (IC50 >100μM).

Keywords: SIRT2; Sirtuin.

MeSH terms

  • Benzamides / chemical synthesis
  • Benzamides / chemistry*
  • Benzamides / metabolism
  • Binding Sites
  • Drug Design*
  • Histone Deacetylase Inhibitors / chemical synthesis*
  • Histone Deacetylase Inhibitors / chemistry
  • Histone Deacetylase Inhibitors / metabolism
  • Humans
  • Molecular Docking Simulation
  • Protein Binding
  • Protein Structure, Tertiary
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / genetics
  • Sirtuin 1 / antagonists & inhibitors
  • Sirtuin 1 / metabolism
  • Sirtuin 2 / antagonists & inhibitors*
  • Sirtuin 2 / genetics
  • Sirtuin 2 / metabolism
  • Sirtuin 3 / antagonists & inhibitors
  • Sirtuin 3 / metabolism
  • Structure-Activity Relationship

Substances

  • Benzamides
  • Histone Deacetylase Inhibitors
  • Recombinant Proteins
  • benzamide
  • Sirtuin 1
  • Sirtuin 2
  • Sirtuin 3